No quarterly revenue total was found in Edgewise Therapeutics, Inc.'s SEC filings.
Edgewise Therapeutics, Inc. (EWTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$78.3 million. As of Sep 30, 2026 it held $1.7 billion in cash and investments and $3.4 million in total debt.
Revenue
—
Net income
$1.17B
+2967.6% vs year-ago quarter
Operating cash flow
$-78.29M
-125.1% vs year-ago quarter
Free cash flow
$-78.31M
-124.0% vs year-ago quarter
EPS
$9.65
+2574.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
109.48M
+3.4% vs year-ago quarter
Net cash
$1.74B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EWTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1710072
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$46.1M | -$61.9M | -$54.1M | -$56.0M | -$46.9M |
| Net income | $1.2B | -$57.3M | -$49.0M | -$50.2M | -$40.7M |
| Diluted EPS | $9.65 | -$0.53 | -$0.46 | -$0.47 | -$0.39 |
| Operating cash flow | -$78.3M | -$42.5M | -$42.5M | -$38.6M | -$34.8M |
| Free cash flow | -$78.3M | -$42.5M | -$42.8M | -$38.7M | -$35.0M |
| Total assets | $1.8B | $479.7M | $518.5M | $552.6M | $583.5M |
| Total liabilities | $147.4M | $31.6M | $25.3M | $30.3M | $24.8M |
| Stockholders' equity | $1.6B | $448.1M | $493.2M | $522.3M | $558.6M |
| Cash and investments | $1.7B | $460.7M | $499.6M | $530.1M | $563.3M |
| Total debt | $3.4M | $3.6M | $3.8M | $4.0M | $4.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K/A | Amended current report | Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Jul 13, 2026 | Jul 10, 2026 |
All 422 Edgewise Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.